MedTrace Logo

A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis

NCT03492398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2021-01-29

Study results available
· View outcomes & findings →

Summary

A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in healthy male volunteers as a possible treatment option for atopic dermatitis

Conditions

Interventions

DRUG

HY209

6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Sponsors & Collaborators

  • Shaperon

    lead INDUSTRY

Principal Investigators

  • Kyungsang Yu, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2019-03-21
Completion
2019-05-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492398 on ClinicalTrials.gov